HIGH

Eptifibatide Injection Recalled Over Labeling Error

Slate Run Pharmaceuticals recalled Eptifibatide Injection on February 12, 2026. The recall affects all lots of the 75 mg/100 mL vial due to incorrect dosing information. Healthcare providers and consumers must stop using the product immediately.

Quick Facts at a Glance

Recall Date
February 12, 2026
Hazard Level
HIGH
Brands
EPTIFIBATIDE, Slate Run Pharmaceuticals, LLC
Category
Health & Personal Care
Sold At
Multiple Retailers
Geographic Scope
1 states
At-Risk Groups
GENERAL

Hazard Information

Labeling: Not Elsewhere Classified. The carton for Eptifibatide Injection 75 mg/100 mL states 75 mg/100 mL vial for weight-adjusted bolus dosing. The approved statement is 75 mg/100 mL vial for weight-adjusted infusion.

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Slate Run Pharmaceuticals or your healthcare provider for guidance. Notification method: Letter

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

About This Product

Eptifibatide Injection is a medication used in healthcare settings as an anticoagulant. It is typically administered intravenously during procedures to prevent blood clots.

Why This Is Dangerous

The product's labeling error can lead to incorrect dosing, which may affect patient safety during treatment. Administering a bolus dose instead of an infusion can lead to serious complications.

Industry Context

This recall is not part of a broader industry pattern.

Real-World Impact

Consumers must stop using the product immediately, which could impact treatment plans for patients. The urgency to correct the labeling can lead to temporary disruptions in care.

Practical Guidance

How to identify if yours is affected

  1. Check the product packaging for NDC numbers.
  2. Verify if the vial states 'bolus dosing' instead of 'infusion.'
  3. Look for expiration dates on the product.

Where to find product info

The NDC numbers can be found on the carton label or the product packaging itself.

What timeline to expect

Expect a timeline of 4-6 weeks for refund processing after returning the product.

If the manufacturer is unresponsive

  • Contact the FDA for further assistance.
  • Document your communication attempts with Slate Run Pharmaceuticals.
  • File a complaint with the FDA if necessary.

How to prevent similar issues

  • Always check product labels before use.
  • Verify dosing instructions with a healthcare provider.
  • Stay informed about recalls through FDA notifications.

Documentation advice

Keep records of your purchase, correspondence with the manufacturer, and photographs of the product for your records.

Product Details

Eptifibatide Injection comes in a 75 mg/100 mL single-dose vial for intravenous use. It is manufactured by Hainan Poly Pharm. Co., Ltd., and distributed by Slate Run Pharmaceuticals. The product carries NDC numbers 70436-027-80 and 70436-163-80.

Key Facts

  • Recall date: February 12, 2026
  • Reported date: March 4, 2026
  • Class III recall status
  • Nationwide distribution in the USA

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
6/ 10
Affected Groups
GENERAL
Injury Types
OTHER

Product Classification

Product Details

Model Numbers
All lots within expiry
UPC Codes
70436-026
70436-027
70436-162
+5 more
Affected States
ALL
Report Date
March 4, 2026
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls

Vehicles & Parts
HIGH

Mazda CX-70 Recall 2025 for Powertrain Control Module Software May Lose Drive Power

Mazda North American Operations is recalling 2024 CX-90 and 2025 CX-70 SUVs sold through Mazda dealers. The PCM and ECM software can illuminate malfunction indicator lights and cause a loss of drive power, increasing crash risk. Owner notification letters were mailed December 19, 2024, and Mazda will reprogram the PCM and ECM at no charge.

Mazda
Loss of
Read more
Vehicles & Parts
HIGH

Nissan Kicks 2025 Certification Label Recall for GVWR/GAWR Errors (PD136, PMA47)

Nissan North America is recalling certain 2025 Nissan Kicks vehicles sold through Nissan dealers nationwide. The certification label may print incorrect GVWR and GAWR values, risking overload. Some SR trims with a 19-inch wheel package may display an incorrect wheel size on the label, and owners should contact their Nissan dealer to arrange replacement labels.

Nissan
An overloaded
Read more